Novo Nordisk’s obesity drug, WeGovy (component name Semaglutide), has been released across the United States.
Novo Nordisk said its WeGovi pill has been launched in the United States. It is the first edible GLP-1 (glucagon-like peptide-1) for adult weight loss.
Approved doses are 1.5 mg (starting dose), 4 mg, 9 mg, and 25 mg. As a result of the previous clinical trial (OASIS 4), when the treatment was continued with 25 mg of gastric emptying, the average weight loss was about 17%. Regardless of whether the treatment was continued or not, the average weight loss was about 14%. According to Novo Nordisk, this is the same level of effect as the gastric emptying injection 2.4 mg.
Clinical adverse reactions were also similar to 2.4 mg injections such as nausea, diarrhea, and vomiting.
According to the U.S. launch, patients can easily achieve meaningful weight loss in their daily lives by taking oral doses once a day.
The starting dose of the Hugo Bee pill (1.5 mg) is $149 per month ($5 per day). The 4 mg dose will be available for $149 per month until April 15, after which it will be available for $199 per month and $299 for the highest dose.
The Hugobee pill is sold through more than 70,000 U.S. pharmacies, including CVS and Costco, and some telemedicine providers.
Novo Nordisk said it is pursuing strategic cooperation to provide drugs to more patients in a variety of ways. The move is aimed at helping patients use genuine, FDA-approved drugs and avoid unsafe alternative drugs.
JULIE KIM
US ASIA JOURNAL
